Eight Small-Cap Medtechs with Big Prospects: Brian Marckx
Source: George S. Mack of The Life Sciences Report  (8/7/13)
Small-cap medical technology has long been regarded as the ugly duckling of biotech. . .but think again. Brian Marckx of Zacks Small-Cap Research believes that the real gems of the medtech space complement—and can even outshine—sexier drug and surgical therapies. In this interview with The Life Sciences Report, Marckx makes a strong case for eight small- and micro-cap names that could bring home huge returns for investors. More >

Our Worry-Free Way of Investing in Biotech
Source: Greg Madison, Money Morning  (8/2/13)
"We are on the cusp of some truly amazing discoveries. There is a tier of biotech companies working around the clock on products with amazing potential." More >

Off to the Races with Seven Extraordinary Biotech and Medtech Companies: Jason Napodano
Source: George S. Mack of The Life Sciences Report  (8/1/13)
Senior Biotechnology Analyst Jason Napodano of Zacks Investment Research specializes in uncovering small biotech and medtech companies with good prospects for successful drug development. He relishes proven management capable of creative financing to move private equity into the public markets, and he does not shy away from tiny companies outside the U.S. that have extraordinary technology. In this wide-ranging interview with The Life Sciences Report, Napodano presents the elegant growth stories of seven small companies that could return magnificent gains to investors. More >

Six Oncology-Focused Biotech Growth Engines: Mara Goldstein
Source: George S. Mack of The Life Sciences Report  (8/1/13)
For Cantor Fitzgerald Senior Biotechnology Analyst Mara Goldstein, the spotlight is always on oncology and the premium revenues commanded by new products in the space. That clarity brings the science, unmet needs and market opportunity into sharp focus for investors. In this interview with The Life Sciences Report, Goldstein makes a winning case for six cancer-focused companies that range from micro caps to genuine large-cap stocks, each with upside potential that could be stunning. More >

Meet High Risk and High Reward, Biotech's Profit Partners: Bert Hazlett
Source: George S. Mack of The Life Sciences Report  (7/25/13)
Small-cap biotech investing carries real risk. Startup companies tend to have only a few ideas in development, which leaves ample room for setbacks—even room for disaster. Robert "Bert" Hazlett, senior biotechnology research analyst with ROTH Capital Partners, doesn't mind taking such risks, but tempers them with a diversification strategy designed to minimize the impact of potential hiccups and blowups. In this interview with The Life Sciences Report,
Hazlett expands on his strategy and mentions four companies with experienced management teams and high hopes for huge returns.
More >

Mesoblast Ltd. Targets Success in the Degenerative Disc Space
Source: George S. Mack of The Life Sciences Report  (7/25/13)
The biggest challenge in the treatment of degenerative disc disease lies in the inhospitable nature of the intervertebral space, where the blood flow and nutrients necessary to cell survival are in short supply. Mesoblast Ltd. has developed a cell therapy that addresses that challenge, triggering the regenerative qualities of surrounding cells to promote healing. In this interview with The Life Sciences Report, Mesoblast Founder, CEO and Managing Director Silviu Itescu describes the science that promises relief to millions of back pain sufferers. More >

BioRestorative Therapies Inc. Develops Plug-and-Play Therapy for Bulging/Herniated Disc Disease
Source: George S. Mack of The Life Sciences Report  (7/25/13)

Millions of people suffer back pain caused by herniated and bulging disc disease. When conventional medical therapies fail they often resort to surgery for relief, a costly and time-consuming solution for both patients and the medical system. In this interview with The Life Sciences Report, Mark Weinreb, president, CEO and chairman of BioRestorative Therapies Inc., describes how his company's cell therapy process could keep disc disease treatment out of the operating theater.

Is Cell Therapy the 'Future of Medicine'?: Jason Kolbert
Source: George S. Mack of The Life Sciences Report  (7/25/13)
The pricey evolutionary tradeoff for walking on two legs is the curse of lower back pain. Jason Kolbert of the Maxim Group understands the power of stem cells as disease-modifying therapies for degenerative disc disease of the spine, a leading-edge, multibillion-dollar indication. Kolbert explores the opportunities that cell therapies offer investors in this interview with The Life Sciences Report, and puts a personal spin on their regenerative promise. More >

Raghuram 'Ram' Selvaraju on the Best Biotech Ideas of 2013
Source: George S. Mack of The Life Sciences Report   (7/18/13)
Small-cap, oncology-focused biotechs with novel technologies have always been bestsellers for investors. Subplots have emerged along the way, but Aegis Capital Corp.'s Managing Director and Head of Healthcare Equity Research Raghuram "Ram" Selvaraju maintains that these companies continue to drive the biotech story forward. In this interview with The Life Sciences Report, Selvaraju reflects on the state of the industry and shares reams of information on specific ideas for investors. More >

The Growing Appetite for Biotech: Pooya Hemami
Source: Peter Byrne of The Life Sciences Report  (7/11/13)
When should investors jump on a junior biotech stock with a promising product in the pipeline? That's a tricky question, one that analyst Pooya Hemami of Edison Investment Research considers carefully as he tracks astonishing epigenetic-based and orphan drugs with novel applications. In this interview with The Life Sciences Report, Hemami describes how he assesses the viability of a junior firm and gives the nod to several well-positioned names in Planet Biotech. More >

Silver's Antibiotic Potential
Source: Geoff Candy, Mineweb  (7/9/13)
"Recent studies have shown that silver can significantly improve the efficacy of antibiotics." More >

Biotechs Burning Rubber with Fundraising in Overdrive
Source: Peter Winter, BioWorld Insight  (7/8/13)
"Over the past 12 months the number of "billion dollar" market cap biotech companies has increased by 51%." More >

Recognizing the Disruptive Potential of Cancer Immunotherapy
Source: Michael Becker, Life Science Digest  (7/8/13)
"Looking ahead over the coming months, there is reason for optimism regarding the next wave of phase 3 results from ongoing cancer vaccine trials. This is due to the fact that many of these products address the limitations of prior cancer vaccine approaches and/or have support from big pharma." More >

How a Professional Investor Uses Twitter to Trade Smarter: Mike Havrilla
Source: George S. Mack of The Life Sciences Report   (7/2/13)
Drug development is full of surprises, and those surprises are hitched to the catalysts that move biotech company stocks. Mike Havrilla, co-founder and analyst with BioRunUp, processes and trades on the news flow surrounding biotech and specialty pharma companies as they navigate the turbulent development cycle. In this interview with The Life Sciences Report, Havrilla talks about his methods and shares three rich ideas that could create doubles or triples for investors. More >

Small-Cap Biotechs with Blockbuster Potential: Hugh Cleland
Source: George S. Mack of The Life Sciences Report   (6/27/13)
Canadian portfolio manager Hugh Cleland of BluMont Capital has chosen an interesting niche. He invests in stocks too small for mutual funds and major institutions, which allows him to get in on the ground floor and capture huge gains when the companies begin to mature. He actively participates in each company's destiny, much like a venture capitalist. In this interview with The Life Sciences Report, Cleland discusses his "core four" and tosses in a handful of speculative tiny-cap companies that investors with enthusiasm for diligence should investigate. More >

Five 'Red Hot' Biotechs: Chen Lin
Source: Zig Lambo of The Life Sciences  (6/27/13)
Breakthrough therapies with billion-dollar market potential are what every biotech company seeks—and what every investor wishes for. Narrowing choices and focusing on opportunities with multibagger potential is the goal of every investor, and few do it better than Chen Lin, author of the popular stock newsletter What Is Chen Buying? What Is Chen Selling? In this interview with The Life Sciences Report, Lin focuses his analytical expertise on the biotech sector and names companies with blockbuster promise. More >

Orphan Drugs Find Home in Transformational Biotech
Source: Patrick Cox, Daily Reckoning  (6/27/13)
"Drugs eligible for PRVs are, by definition, orphan disease drugs. As a result, orphan drug candidates get valuable special treatment from regulators." More >

How to Invest in the Golden Age of Biotech
Source: Diane Alter, Money Morning  (6/26/13)
"Propelled by new drug debuts, research advances and a full pipeline, a long stretch of rewarding breakthrough products should continue to flow in the years ahead." More >

Deadly Bacteria Are a Global Crisis: Brad Spellberg
Source: George S. Mack of The Life Sciences Report  (6/20/13)
Antibiotic-resistant bacteria, like the proverbial time bomb, are poised to wreak infectious havoc on a worldwide scale. Brad Spellberg, associate professor of medicine at the Los Angeles Biomedical Research Institute and the Harbor-UCLA Medical Center, is committed to defusing the bomb with the development of new antibiotics and creative platforms. He believes investigators must look at alternative ways to deal with bad bugs, perhaps by neutralizing their toxic effects rather than killing them. In this interview with
The Life Sciences Report, Spellberg explores this critical issue and names four companies with novel technologies that address this looming global crisis.
More >

New Biotech Names with Excellent Prospects: Michael Aitkenhead
Source: George S. Mack of The Life Sciences Report  (6/13/13)
In a marketplace as diverse as biotech, picking the best and brightest can stymie even the savviest investor. Senior biotechnology analyst and physician Michael Aitkenhead of Edison Investment Research has done meticulous research on both the science and unmet needs to reveal the growth potential of biotechs with vastly different stories, disease indications and markets. In this interview with The Life Sciences Report, Aitkenhead details his thesis on three names, each with the ability to return large multiples on original investment. More >

For Love and Money: Three Growth Stocks from Casey's Alex Daley
Source: George S. Mack of The Life Sciences Report  (6/13/13)
Alex Daley, senior editor of Casey Extraordinary Technology, seeks out undiscovered names because that's where he finds the big upside. In this interview with The Life Sciences Report, Daley brings his best ideas to investors who won't shy away from unloved biotech and medtech names. Sharpen your pencils, steel your nerves and take note of these three growth stories. More >

Mixed News for Biotech Industry: Supreme Court Upends Gene Patents
Source: Genetic Engineering and Biotechnology News  (6/13/13)
" 'A naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, but cDNA is patent eligible because it is not naturally occurring,' the court stated in an opinion written by Justice Clarence Thomas." More >

Seven Biotech Options that Buck Tradition: Christian Glennie
Source: George S. Mack of The Life Sciences Report  (6/6/13)
Edison Investment Research assesses the value of emerging companies with a model that assumes revenues and earnings are years away. Then again, every investor does that. What's unusual is that Edison looks for tomorrow's upside in companies still small enough to double, triple and quadruple in value down the line. In this interview with The Life Sciences Report,
Edison Biotechnology Analyst Christian Glennie applies his valuation skills to seven innovative biotech and specialty pharma companies and discusses the share-moving catalysts that investors need to know about now.
More >

How to Play the Invest-for-Tomorrow Game in Medtech: Alan Brochstein
Source: George S. Mack of The Life Sciences Report  (6/6/13)
Alan Brochstein of AB Analytical Services blogs, publishes and creates model portfolios for retail investors and consults with institutional investors. He leans heavily toward medical technology because he sees the industry's devices, instrumentation and molecular diagnostics as huge efficiency creators and money savers for hospitals. He never pulls the trigger on a stock unless it has adequate insider ownership and superb management—two ingredients that almost always lead to success. In this interview with The Life Sciences Report, Brochstein highlights several turnaround stories that he believes can create real shareholder value and make money for investors. More >

Winners and Losers Take Center Stage at ASCO Conference
Source: Genetic Engineering and Biotechnology News  (6/3/13)
"While big pharma delivered on its promise to present encouraging phase 2/3 results at the American Society of Clinical Oncology meeting, the drug giants were in good company—Peregrine Pharmaceuticals and Seattle Genetics were among the smaller biopharmas to report promising clinical data." More >